Operon Ventures spun off from Oxford Bioscience Partners in 2015 and manages the Korea-Seoul Life Science venture capital fund. The firm invests in all stages of venture capital. Operon Ventures targets all sectors of life sciences, including biotechnology, drugs, medical devices, diagnostics, healthcare services and healthcare convergence. The firm will invest in Asia and US.
Venture Capital
1 funds found in our dataset.
Built for investment teams that need to move faster.
Intelligently process data room financials, generate auditable analyses, and export IC-ready deliverables.